M.-H. Ryu

741 total citations
27 papers, 578 citations indexed

About

M.-H. Ryu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, M.-H. Ryu has authored 27 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 9 papers in Surgery. Recurrent topics in M.-H. Ryu's work include Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (11 papers) and Gastrointestinal Tumor Research and Treatment (9 papers). M.-H. Ryu is often cited by papers focused on Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (11 papers) and Gastrointestinal Tumor Research and Treatment (9 papers). M.-H. Ryu collaborates with scholars based in South Korea, Japan and United States. M.-H. Ryu's co-authors include Y-K. Kang, Jia-Lin Lee, Heung-Moon Chang, B-Y. Ryoo, Dok Hyun Yoon, H.-M. Chang, Tae‐Won Kim, Dae Young Zang, Young Joo Min and Hye Jin Kang and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

M.-H. Ryu

26 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.-H. Ryu South Korea	13	364	295	196	140	85	27	578
B-Y. Ryoo South Korea	9	332 0.9×	313 1.1×	166 0.8×	115 0.8×	76 0.9×	36	581
Mao-Chih Hsieh Taiwan	16	453 1.2×	181 0.6×	342 1.7×	216 1.5×	69 0.8×	29	752
Kuhn‐Uk Lee South Korea	8	410 1.1×	417 1.4×	256 1.3×	138 1.0×	56 0.7×	9	714
Véronique Guerin‐Meyer France	10	309 0.8×	662 2.2×	177 0.9×	60 0.4×	117 1.4×	32	820
Makio Gamoh Japan	11	248 0.7×	328 1.1×	109 0.6×	95 0.7×	60 0.7×	49	484
Yasushi Mitachi Japan	9	711 2.0×	732 2.5×	295 1.5×	189 1.4×	128 1.5×	18	1.1k
Daisuke Korenaga Japan	12	245 0.7×	137 0.5×	194 1.0×	98 0.7×	60 0.7×	30	445
Akiko Todaka Japan	16	372 1.0×	390 1.3×	335 1.7×	69 0.5×	66 0.8×	80	688
Keun Wook Lee South Korea	14	299 0.8×	499 1.7×	201 1.0×	104 0.7×	90 1.1×	41	745
Mehmet Küçüköner Türkiye	14	253 0.7×	230 0.8×	115 0.6×	33 0.2×	116 1.4×	74	591

Countries citing papers authored by M.-H. Ryu

Since Specialization

Citations

This map shows the geographic impact of M.-H. Ryu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.-H. Ryu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.-H. Ryu more than expected).

Fields of papers citing papers by M.-H. Ryu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.-H. Ryu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.-H. Ryu. The network helps show where M.-H. Ryu may publish in the future.

Co-authorship network of co-authors of M.-H. Ryu

This figure shows the co-authorship network connecting the top 25 collaborators of M.-H. Ryu. A scholar is included among the top collaborators of M.-H. Ryu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.-H. Ryu. M.-H. Ryu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ju, Sang-Yhun, Seungju Lee, M.-H. Ryu, et al.. (2025). Effects of Chemotherapy (Anthracyclin, Cyclophosphamide following Docetaxel Regimen) on Sleep, Anxiety, Depression, and Quality of Life in Patients with Breast Cancer. Oncology. 103(11). 974–984. 2 indexed citations

Lee, Seungju, Hyun Yul Kim, M.-H. Ryu, et al.. (2025). Identification of Poor Prognostic Markers in Triple-Negative Breast Cancer Using Whole Exome Sequencing. Journal of Breast Cancer. 28(6). 406–406.

Boku, Narikazu, M.-H. Ryu, D-Y. Oh, et al.. (2020). LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Annals of Oncology. 31. S1192–S1192. 80 indexed citations

Kang, Yoon‐Koo, Keisho Chìn, Hyun Cheol Chung, et al.. (2019). A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study). Annals of Oncology. 30. iv153–iv153. 3 indexed citations

Ryu, M.-H., Yubin Kang, Kwang Pyo Kim, et al.. (2016). Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Annals of Oncology. 27. vi234–vi234. 14 indexed citations

Lee, Jia-Lin, M.-H. Ryu, Heung Moon Chang, et al.. (2012). Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. British Journal of Cancer. 106(10). 1591–1597. 13 indexed citations

Yoon, Dok Hyun, M.-H. Ryu, Heon‐Jin Lee, et al.. (2012). Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British Journal of Cancer. 106(6). 1039–1044. 70 indexed citations

Jang, Geundoo, Kyun‐Seop Bae, Hei Sung Kim, et al.. (2011). Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. British Journal of Cancer. 104(4). 605–612. 25 indexed citations

Ryu, M.-H., et al.. (2011). A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.. Journal of Clinical Oncology. 29(15_suppl). 10010–10010. 4 indexed citations

10.

Yoon, Dok Hyun, Baek‐Yeol Ryoo, M.-H. Ryu, et al.. (2010). Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Japanese Journal of Clinical Oncology. 40(8). 768–773. 66 indexed citations

11.

Han, Sungpil, Seunghyun Bang, T.W. Kim, et al.. (2009). Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. British Journal of Dermatology. 162(2). 371–379. 19 indexed citations

12.

Park, Inkeun, et al.. (2008). Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor. Japanese Journal of Clinical Oncology. 39(2). 105–110. 21 indexed citations

13.

Chang, Heung-Moon, M.-H. Ryu, Jeong Hwan Yook, et al.. (2008). A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. British Journal of Cancer. 98(2). 316–322. 33 indexed citations

14.

Ryu, M.-H., et al.. (2008). Phase I/II and pharmacokinetic study of combination chemotherapy with S-1 and oxaliplatin in patients with previously untreated metastatic or recurrent gastric cancer. Journal of Clinical Oncology. 26(15_suppl). 4557–4557. 1 indexed citations

15.

Jo, Jae‐Cheol, J.-L. Lee, M.-H. Ryu, et al.. (2007). Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis. Japanese Journal of Clinical Oncology. 37(12). 936–941. 32 indexed citations

16.

Chun, Young Il, et al.. (2007). Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. Journal of Clinical Oncology. 25(18_suppl). 9007–9007. 9 indexed citations

17.

Chang, Heung-Moon, Tae‐Won Kim, M.-H. Ryu, et al.. (2005). Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. British Journal of Cancer. 92(2). 246–251. 31 indexed citations

18.

Lee, J.-L., et al.. (2005). Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 4220–4220. 5 indexed citations

19.

Kim, T. W., et al.. (2004). A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy. Journal of Clinical Oncology. 22(14_suppl). 4051–4051. 4 indexed citations

20.

Chang, Heung-Moon, et al.. (2004). Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 4219–4219. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact